No Data
No Data
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) Last Week's 5.9% Decline Must Have Disappointed Individual Investors Who Have a Significant Stake
Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Shareholders Have Earned a 22% CAGR Over the Last Five Years
Investors Still Aren't Entirely Convinced By Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) Earnings Despite 25% Price Jump
Tianjin Pharmaceutical's Q1 Profit, Revenue Fall 3%
Daren Tang (600329.SH): Net profit for the first quarter was 387 million yuan, down 3.36% year on year
On April 29, Ge Longhui (600329.SH) released its report for the first quarter of 2024. During the reporting period, it achieved operating income of 2,086 billion yuan, a year-on-year decrease of 3.19%; net profit attributable to shareholders of listed companies was 387 million yuan, a year-on-year decrease of 3.36%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 376 million yuan, a year-on-year decrease of 4.84%; and basic earnings per share were 0.50 yuan.
Is Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) A Risky Investment?
No Data